EARLY USE OF VEDOLIZUMAB VERSUS INFLIXIMAB IN BIOLOGIC-NAIVE PATIENTS WITH ULCERATIVE COLITIS: A REAL-WORLD ANALYSIS OF HEALTHCARE UTILIZATION

被引：0
|
作者：
Patel, Haridarshan
Khalid, Javaria M.
Shah, Surbhi
Shah, Rikisha
Berger, Ariel
机构：
来源：
GASTROENTEROLOGY | 2018年 / 154卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Sa1728
引用
收藏
页码：S371 / S371
页数：1
相关论文
共 50 条
  • [1] Early use of vedolizumab vs. infliximab in biologic-naive patients with ulcerative colitis: A real-world analysis of healthcare utilisation
    Patel, H.
    Khalid, J. M.
    Shah, S.
    Shah, R.
    Berger, A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S385 - S386
  • [2] A real-world study of outcomes in biologic-naive patients with Crohn's disease and ulcerative colitis initiating vedolizumab
    Raluy, M.
    Alam, N.
    Donaldson, R.
    Smyth, M.
    Khalid, J. M.
    [J]. JOURNAL OF CROHNS & COLITIS, 2016, 10 : S238 - S238
  • [3] COMPARISON OF REAL-WORLD TREATMENT OUTCOMES WITH INFLIXIMAB VERSUS VEDOLIZUMAB IN BIOLOGIC-NAIVE PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Latremouille-Viau, Dominick
    Burne, Rebecca
    Shi, Sherry
    Adsul, Shashi
    Patel, Haridarshan
    [J]. GASTROENTEROLOGY, 2019, 156 (06) : S638 - S639
  • [4] Clinical Effectiveness and Safety of Vedolizumab vs. Infliximab in Biologic-Naive Ulcerative Colitis Patients: A Brazilian Real-World Multicentric Observational Study
    Ferreira, S.
    Chebli, J. M. F.
    Parra, R.
    Sassaki, L. Yukie
    de Mello, M. K.
    Luporini, R. L.
    Chebli, L. A.
    Nobrega, F. J. Firmino
    da Silva, B. C.
    Dutra, R. D. M.
    Vasconcelos, J. R. de Oliveira
    Sales, M. P. Moraes
    Feres, O.
    Parente, J. M. L.
    Troncon, L. E. D. A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1087 - I1088
  • [5] Comparison of Real-World Treatment Outcomes With Vedolizumab Versus Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease
    Patel, Haridarshan
    Latremouille-Viau, Dominick
    Burne, Rebecca
    Shi, Sherry
    Adsul, Shashi
    [J]. CROHNS & COLITIS 360, 2019, 1 (02)
  • [6] Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naive Korean Patients with Ulcerative Colitis: A Population-Based Study
    Han, Minkyung
    Jung, Yoon Suk
    Cheon, Jae Hee
    Park, Sohee
    [J]. YONSEI MEDICAL JOURNAL, 2020, 61 (01) : 48 - 55
  • [7] Vedolizumab is superior to infliximab in biologic naive patients with ulcerative colitis
    Sablich, Renato
    Urbano, Maria Teresa
    Scarpa, Marco
    Scognamiglio, Federico
    Paviotti, Alberto
    Savarino, Edoardo
    [J]. SCIENTIFIC REPORTS, 2023, 13 (01)
  • [8] Editorial: Is vedolizumab the preferred biologic therapy for biologic-naive patients with ulcerative colitis?
    Yamamoto, Takayuki
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 58 (05) : 546 - 547
  • [9] Cytomegalovirus Colitis Is Rarely Observed After Initiation of Infliximab, Adalimumab, or Vedolizumab in Biologic-Naive Patients With Ulcerative Colitis
    Dalal, Rahul S.
    McClure, Emma L.
    Pruce, Jordan C.
    Allegretti, Jessica R.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S334 - S335
  • [10] USE OF DIFFERENT STATISTICAL APPROACHES TO COMPARE REAL-WORLD OUTCOMES ASSOCIATED WITH VEDOLIZUMAB VERSUS INFLIXIMAB IN BIOLOGIC-NAIVE PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Latremouille-Viau, D.
    Burne, R.
    Shi, S.
    Patel, H.
    [J]. VALUE IN HEALTH, 2019, 22 : S178 - S178
12345